Biomarkers for interferon response in MS: are we there yet?
Rudick
Richard A
RA
Ransohoff
Richard M
RM
D000906:Antibodies / Q000097:blood / Q000276:immunology; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D004351:Drug Resistance / Q000235:genetics / Q000276:immunology; D019204:GTP-Binding Proteins / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology; D006801:Humans; D016899:Interferon-beta / Q000494:pharmacology* / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008991:Monitoring, Physiologic / Q000592:standards; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000276:immunology; D064547:Myxovirus Resistance Proteins; D011237:Predictive Value of Tests; D012333:RNA, Messenger / Q000032:analysis / Q000097:blood* / Q000187:drug effects*; D016896:Treatment Outcome
D000906:Antibodies; D015415:Biomarkers; D064547:Myxovirus Resistance Proteins; D012333:RNA, Messenger; D016899:Interferon-beta; D019204:GTP-Binding Proteins